Clinical Trial Update: Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tildrakizumab for prevention of acute graft-versus-host disease in patients with hematologic malignancies has completed; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Tildrakizumab (tildrakizumab)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Hematologic Malignancies | Phase 2 | Status: COMPLETED | Results posted: 2025-07-04